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Objective: Benzodiazepines are an increasingly prescribed class of anxiolytic medications that 
target GABA-A receptors in the brain. Smoking also has indirect effects on GABA receptors. 
This secondary data analysis evaluates the effects of benzodiazepine use on smoking cessation 
rates among participants in a hospital-based cessation trial. To our knowledge, no other study has 
examined the effect of benzodiazepine use on smoking cessation rates. 
Methods: Data from the Enhancing Quitline Utilization among In-Patients (EQUIP) study was 
analyzed as part of a secondary data analysis. Participants with a benzodiazepine prescription 
listed on their hospital discharge medication list were compared with those without a 
benzodiazepine prescription (total n=1054). Similar analyses were conducted between 
participants with either a long- or short-acting benzodiazepine prescription. 
Results: A logistic regression modeling the odds of a participant quitting showed no statistical 
association with benzodiazepine prescription presence (Odds Ratio, OR, 0.93, 95% confidence 
interval 0.68, 1.28). Controlling for potential covariates maintained a negatively associated, non-
significant OR of 0.88 (95% confidence interval 0.63, 1.22).  Additionally, the logistic regression 
modeling produced non-significant odds ratios for both unadjusted and adjusted associations of 
long-acting versus short-acting benzodiazepine prescription presence on quit rates (adjusted O.R. 
0.88, 95% confidence interval 0.49, 1.61). 
Conclusions: In this sample of patients, the presence of a benzodiazepine prescription at 
discharge did not have a significant effect on 6-month biochemically verified quit rates. The 
odds of being quit based on the presence of a benzodiazepine prescription at discharge trended 
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Smoking is the top preventable cause of death in the United States.  Roughly forty 
percent of smokers attempt to quit each year[1]. Benzodiazepines are an increasingly prescribed 
class of anxiolytic medications that target GABA-A receptors[2]. Benzodiazepines could help or 
hinder smokers’ ability to quit in several ways. Benzodiazepine use could hinder smokers’ ability 
to quit because both chronic use of benzodiazepines[3] and smoking[4] can each independently 
affect GABA receptor function in the brain. Quitting either benzodiazepines or smoking leads to 
a decreased activation of GABA receptors. This lower activation has been linked to anxiety[5]. 
Anxious symptoms are a major barrier to staying quit[6]. Conversely, benzodiazepines could 
enhance smokers’ likelihood of staying quit. As an anxiolytic, short-term use of benzodiazepines 
could reduce symptoms of anxiety that occur during quit attempts by binding to unbound GABA 
receptors previously affected by tobacco smoke. 
 The type of benzodiazepine taken could have a differential effect on smoking cessation. 
Benzodiazepines are categorized by duration of action. Symptomatic coverage differs between 
long (>24 hour half-life) and short (<24 hour half-life) acting benzodiazepines[7]. The difference 
in duration of action may lead to differential GABA receptor coverage, affecting receptor 
availability in the brain. Specifically, shorter-acting benzodiazepines could create peaks and 
troughs in receptor coverage; tobacco use could alleviate symptoms that emerge during trough 
levels. This relationship could maintain tobacco use and make it difficult to quit. To our 
knowledge, no study has examined the impact of benzodiazepine prescriptions on smoking 




 The objective of this secondary data analysis was to determine the effects of 
benzodiazepine use on smoking cessation rates among participants in a hospital-based cessation 
trial. A subgroup analysis was conducted to detect differences in smoking cessation rates 
between long- and short-acting benzodiazepine use. 
Methods 
Study Design 
The Enhancing Quitline Utilization among In-Patients (EQUIP) study is a two-arm 
randomized clinical trial designed to examine the impact of warm handoff on enrollment in 
quitline services and biochemically verified cessation at 6-months [8]. The purpose of EQUIP 
was to determine the relative effectiveness of warm handoff versus fax referral for transitioning 
inpatient smokers to post-discharge care. Participants in both study arms received the hospital’s 
standard cessation brochure with information and resources for quitting smoking. Those in the 
fax referral group were provided the institution specific tobacco treatment service and were fax-
referred to the quitline on the day they were discharged from the hospital. Those in the warm 
handoff group were personally connected with the quitline during their hospital stay. Follow-up 
was performed based on decisions made during this quitline counseling session. The study 
design and details are described in a prior publication [8]. We conducted a secondary data 
analysis of the study that examines the effects of benzodiazepine prescription at hospital 
discharge on biochemically verified cessation at 6-months.   
Setting and Participants 
Participants (n=1054) were smokers admitted into two large hospitals in Kansas with 




quit post-discharge, smoking any cigarettes within the past 30 days, being aged 18 or older, 
speaking English or Spanish, having access to a telephone post-discharge, having no other 
household member participating in the trial, not currently pregnant, and having no co-morbidity 
or health issue preventing full participation.  
 Measures  
 Demographics, highest level of education, tobacco use characteristics, Heaviness of 
Smoking Index (HSI)[9], Alcohol Use Disorder Identification Test (AUDIC-C)[10], and the 
Patient Health Questionnaire-2 (PHQ-2)[11] were obtained through the baseline survey. 
Discharge prescriptions, primary diagnoses, procedures, and length of stay were obtained from 
the electronic medical record (EMR). Psychiatric disorders and participants who had undergone 
cardiac or cerebrovascular surgery were identified using the Ninth Revision of the International 
Classification of Disease (ICD-9) and Diagnosis Related Group (DRG) codes. 
Benzodiazepine medications were identified through discharge prescriptions abstracted 
from the EMR. Such medications were identified by drug name and categorized by active 
metabolite duration of action. Benzodiazepines with an average half-life exceeding 24 hours 
were categorized as long-acting agents (chlordiazepoxide, clonazepam, clorazepate, and 
diazepam). Benzodiazepines with an average half-life less than 24 hours were categorized as 
short-acting agents (alprazolam, lorazepam, and temazepam)[7].  
 As described in the design paper of EQUIP [8], abstinence was assessed with two 
measures. The first measure, self-reported abstinence at 1 and 6 months, was obtained by asking 
participants if they had smoked any cigarettes in the past 7 days. The second measure of 




ppm), or proxy. Participants who failed to verify abstinence were counted as smokers in the final 
analysis.   
 Data Analyses  
Because participants were not randomized by benzodiazepine prescription presence, we 
first determined baseline differences between groups.  For all primary objective analyses, 
participants with a benzodiazepine prescription listed on their hospital discharge medication list 
were compared with those without a benzodiazepine prescription. These groups were compared 
with respect to demographics, tobacco use, hospital treatment, health behavior and psychosocial 
measures, and discharge medications. Similar analyses for the secondary objective were 
conducted between participants with either a long- or short-acting benzodiazepine prescription. 
Baseline measures were investigated using the Student’s t-test and chi square test.  
Next, a chi square test was used to determine unadjusted differences in quit rates between 
the investigated groups in the primary objective analysis (benzodiazepine/no benzodiazepine) 
and secondary objective analysis (long versus short-acting benzodiazepine). Logistic regression 
analyses of 6-month biochemically verified cessation rates were conducted. The logistic 
regression analyses modeled the odds of being quit at month six.  
We also conducted regression analyses for each of the study objectives that adjusted for 
potential confounding variables. Adjustments included baseline differences between groups, 
variables associated with quitting in this sample, and variables predictive of quitting suggested 
by previous literature. Adjustments gleaned from cessation literature included gender, age, 







Comparisons of Demographics Measures. A total of 287 participants (27.2%) were 
prescribed a benzodiazepine at discharge (Table 1). There were no significant differences 
between groups on measures of age, Latino origin, education, or presence of other smokers. 
There were significant differences between the groups in gender, race, insurance status, primary 
diagnosis, surgery status, AUDIT-C, PHQ-2, and opiate prescription presence (p < 0.05). 
Tobacco Use. There were no detectable differences between participants with 
benzodiazepine prescriptions and those without a benzodiazepine prescription in the number of 
cigarettes smoked per day, number of days smoked per month (>25 days/30 days), smoking upon 
awakening, HIS (>4), and confidence levels in staying quit. 
Hospital Treatment. Comparisons between participants with a benzodiazepine 
prescription and those without a benzodiazepine prescription found no detectable differences in 
psychiatric comorbidities, emergency admissions, and length of stay. Participants had 
significantly different primary diagnoses and surgery occurrences. 
Health Behavior and Psychosocial Measures. Participants with benzodiazepine 
prescriptions were less likely to report problematic alcohol use (AUDIT-C) and more likely to 





Discharge Medication. Significantly more opiates were prescribed among those in the 
benzodiazepine prescription group versus those who were not prescribed a benzodiazepine (p < 
0.001). Smoking cessation medications did not differ significantly between these groups. 
Variables Associated With Quitting. Education (< High School), daily smoking (>25 
days/30 days), and hospital length of stay were found to be associated with quit rates among 
those who received a benzodiazepine prescription (p < 0.05) (Not shown).  
 









 (n = 767) 
Demographics    
Age, mean (SD) 49.89 (12.93) 49.01 (12.20) 50.22 (13.19) 
Female, no. (%)* 581 (55.12%) 195 (67.94%) 386 (50.33%) 
Race*    
     White, no. (%) 719 (68.22%) 219 (76.31%) 500 (65.19%) 
     African American, no. (%) 262 (24.86%) 43 (14.98%) 219 (28.55%) 
     Other, no. (%) 73 (6.93%) 25 (8.71%) 48 (6.26%) 
Latino, no. (%) 62 (5.91%) 19 (6.62%) 43 (5.61%) 
Education < High School, no. (%) 231 (21.92%) 62 (21.60%) 169 (22.03%) 
Lives with other smoker, no. (%) 523 (49.62%) 145 (50.52%) 378 (49.28%) 
Primary Insurance*    
     Medicaid, no. (%) 355 (33.68%) 103 (35.89%) 252 (32.86%) 
     Medicare, no. (%) 314 (29.79%) 103 (35.89%) 211 (37.51%) 
     Private, no. (%) 306 (29.03%) 69 (24.04%) 237 (30.90%) 
     VA, no. (%) 12 (1.14%) 3 (1.05%) 9 (1.17%) 
     Self-pay/none, no. (%) 67 (6.36%) 9 (3.14%) 58 (7.56%) 
Tobacco Use    
CPD mean (SD) 15.97 (11.06) 16.14 (12.12) 15.62 (10.62) 
Daily smoking (> 25/30 days), no. 
(%) 




Smoke within 30 mins of waking, 
no. (%) 
753 (71.71%) 206 (71.78%) 547 (71.32%) 
Heavy smoking index (HSI)  >  4 , 
no. (%) 
347 (32.92%) 101 (35.19%) 246 (32.07%) 
Confidence to quit/stay quit 
(possible range 1 – 5), mean (SD) 
3.79 (1.12) 3.84 (1.10) 3.78 (1.12) 
Hospital Treatment    
Reason for admission *    
     Circulatory system, no. (%) 261 (24.76%) 44 (15.33%) 217 (28.29%) 
     Respiratory system, no. (%) 121 (11.48%) 36 (12.54%) 85 (11.08%) 
     Neoplasms, no. (%) 50 (4.74%) 17 (5.92%) 33 (4.30%) 
     Mental Disorders, no. (%) 22 (2.09%) 4 (1.39%) 18 (2.35%) 
     Other, no. (%) 600 (56.93%) 186 (64.81%) 414 (53.98%) 
Psychiatric Co-morbidity, no. (%) 681 (64.6%) 188 (65.51%) 493 (64.28%) 
Cardiac and cerebrovascular 
surgery, no. (%)* 
121 (11.48%) 18 (6.27%) 103 (13.43%) 
Emergency admissions, no. (%) 630 (59.8%) 159 (55.40%) 471 (61.41%) 
Length of stay (hours), mean (SD) 134.88 
(133.10) 
146.76(137.10) 130.43(131.38) 
Health Behavior and Psychosocial 
Measures 
   
Alcohol Use Disorder (AUDIT-C), 
no. (%)* 
323 (30.65%) 53 (18.47%) 270 (35.20%) 
Possible Depression (PHQ-2), no. 
(%)* 
566 (53.80%) 185 (64.46%) 381 (49.67%) 
Discharge Medication    
Opiate medication use, no. (%)* 677 (64.23%) 216 (75.26%) 461 (60.10%) 
Smoking Cessation Medications     
     Nicotine Replacement Therapy 258 (24.48%) 82 (28.57%) 176 (22.95%) 
     Varenicline 30 (2.85%) 11 (3.83%) 19 (2.48%) 
     Bupropion 52 (4.93%) 16 (5.57%) 36 (4.69%) 
*p-value <0.05 
 
Unadjusted Quit Rates by Benzodiazepine Use. No statistical difference was found in 
biochemically verified 6-month quit rates between those who received a benzodiazepine 





A logistic regression modeling the odds of a participant quitting showed no statistical 
association with benzodiazepine prescription presence (OR 0.93, 95% confidence interval 0.68, 
1.28) (Table 2). Addition of a priori predictors, baseline differences, and sample predictors of 
cessation maintained a negatively associated, non-significant OR of 0.88 (95% confidence 
interval 0.63, 1.22).   
Table 2. Odds of Quitting in Presence of Benzodiazepine Prescription 
Explanatory Variables Model 1 Model 2 Model 3 Model 4 
Benzodiazepine 










A Priori predictors - Yes Yes Yes 
Baseline differences - - Yes Yes 
Sample predictors of 
cessation  




Differences in Baseline Characteristics between Long- and Short-Acting Agents. 
More cerebrovascular and cardiac surgeries were conducted in those who received short-acting 
benzodiazepines versus participants who received long-acting benzodiazepines (p=0.043) (Not 
shown). In all other baseline measures no statistical differences were seen. 
Variables associated with quitting. Hospital length of stay was found to be associated 
with quit rates among those who received a long-acting versus a short-acting benzodiazepine 
prescription (p = 0.026).  
Unadjusted Quit Rates by Long- and Short-Acting Benzodiazepine Use. There was 




benzodiazepines and participants prescribed short-acting benzodiazepines (p = 0.648) (Not 
Shown). 
Multivariate Analysis 
The logistic regression modeling produced non-significant odds ratios for both 
unadjusted and adjusted associations of long-acting versus short-acting benzodiazepine 
prescription presence on quit rates (adjusted OR 0.88, 95% confidence interval 0.49, 1.61). 
Table 3. Odds of Quitting between Long- and Short-Acting Benzodiazepine Prescriptions 












A Priori Predictors - Yes Yes Yes 
Baseline differences - - Yes Yes 
Sample predictors of 
cessation  
- - - Yes 
 
Discussion  
In this sample of patients, the presence of a benzodiazepine prescription at discharge did 
not have a significant effect on 6-month biochemically verified quit rates. The odds of being quit 
based on the presence of a benzodiazepine prescription at discharge trended negatively across all 
unadjusted and adjusted analyses. To our knowledge, no other study has examined the effect of 
benzodiazepine use on smoking cessation rates. 
There was no significant difference in quit rates between participants on long- versus 
short-acting benzodiazepines. Interestingly, quit rates were the same between participants with a 





Both tobacco smoke[4] and benzodiazepines[3] have an effect on GABA receptor 
function and availability. This interaction could affect smokers’ ability to quit. Other studies 
have examined the effects of psychoactive medications on smoking cessation. Specifically, 
methadone has been studied for both pharmacokinetic and pharmacodynamic interactions with 
nicotine. These studies have found that pharmacodynamic interactions between opioids and 
nicotine may explain low smoking cessation rates. Biologically, this occurs through synergistic 
activation of endogenous opioid receptors[13].  
Anxiety due to tobacco withdrawal has been associated with GABA receptor dysfunction 
[4]. It was proposed that GABA receptor binding could ameliorate anxiety associated with 
tobacco withdrawal, thus improving overall likeliness to quit among persons taking 
benzodiazepines. This, however, was not borne out by our primary objective analyses. 
Additionally, following the pharmacokinetic patterns of short-acting benzodiazepines, there are 
periods of the day where the GABA receptor may not be bound[7]. Windows of anxious 
symptoms may be more frequent due to this decreased binding; and thus, may lead to more 
relapse than seen with long-acting benzodiazepines. Our secondary objective analyses did not 
detect this effect.  
This secondary data analysis was limited by several factors. Participants in the EQUIP 
trial were not randomized to either receive or not receive benzodiazepines. Although we adjusted 
for baseline differences, there may be other underlying differences between groups that obscured 
any independent effects on quitting that benzodiazepines might have. Also, participants may not 
be representative of average smokers wanting to quit. Non-hospitalized smokers wanting to quit 




to detect the effects of benzodiazepine use on smoking cessation rates. Moreover, presence of a 
benzodiazepine prescription at discharge may not accurately reflect participants’ actual 
utilization of benzodiazepines. Also, we were unable to differentiate between acute and chronic 
benzodiazepine use. Anxiolytic tolerance to benzodiazepines is associated with extended 
duration of use[3]. More research is necessary to determine whether benzodiazepines effect 
smoking cessation. 
While the number of benzodiazepine prescriptions is on the rise[2], little data is available 
on what role benzodiazepines might have in helping or hindering smoking cessation. Our 
preliminary data suggests that no difference in quit rates exists between those with a 
benzodiazepine prescription those without a benzodiazepine prescription. Basic studies should 
better explore the mechanisms through which tobacco smoke affects GABA receptors. Future 
studies should describe the patterns of tobacco use, benzodiazepine use, and psychiatric 
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